Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All evaluated statements about fetal toxicity and pregnancy management accurately reflect the provided Diovan (valsartan) prescribing information (Sections 5.1 and 8.1), including downstream fetal effects and discontinuation guidance.
Category Scores
Accurate Statements
Diovan (valsartan) can cause fetal harm; use during pregnancy (especially 2nd/3rd trimester) reduces fetal renal function and increases fetal/neonatal morbidity and death.
5.1 Fetal Toxicity; 8.1 Pregnancy
Resulting oligohydramnios may be associated with fetal lung hypoplasia and skeletal deformations.
5.1 Fetal Toxicity
Discontinue as soon as possible when pregnancy is detected.
5.1 Fetal Toxicity; 8.1 Pregnancy
Unsupported Statements
Contradictions
Important Omissions
The label also states that most epidemiologic studies examining fetal abnormalities after first-trimester exposure to antihypertensive use (including renin-angiotensin system drugs) have not distinguished renin-angiotensin system drugs from other antihypertensive agents, and that published reports include cases of anhydramnios and oligohydramnios treated with valsartan.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No contraindictory or unsupported claims were made. The evaluated statements align with the label’s fetal toxicity warning and discontinuation guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: first-trimester epidemiology/anhydramnios details present in the label were not included.
Suggested Improvement
Optionally add that label language about first-trimester findings and reported anhydramnios/oligohydramnios cases to fully mirror Sections 5.1 and 8.1.